RG
ALXO icon

Redmile Group’s ALX Oncology ALXO Stock Holding History

Redmile Group’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.3M Sell
7,392,504
-571,684
-7% -$1.02M 1.03% 21
2026
Q1 		$16M Buy
7,964,188
+4,699,470
+144% +$8.95M 1.06% 15
2025
Q4 		$3.69M Sell
3,264,718
-68,265
-2% -$103K 0.27% 31
2025
Q3 		$6.1M Sell
3,332,983
-58,472
-2% -$50.6K 0.59% 28
2025
Q2 		$1.41M Sell
3,391,455
-249,379
-7% -$126K 0.15% 45
2025
Q1 		$2.27M Sell
3,640,834
-48,777
-1% -$58.6K 0.21% 49
2024
Q4 		$6.16M Sell
3,689,611
-146,965
-4% -$226K 0.43% 42
2024
Q3 		$6.98M Sell
3,836,576
-199,875
-5% -$743K 0.41% 41
2024
Q2 		$24.3M Sell
4,036,451
-290,058
-7% -$3.57M 1.47% 28
2024
Q1 		$48.2M Buy
4,326,509
+667,245
+18% +$9.37M 1.77% 18
2023
Q4 		$54.5M Buy
3,659,264
+2,375,975
+185% +$22.5M 1.95% 13
2023
Q3 		$6.16M Hold
1,283,289
– – 0.29% 51
2023
Q2 		$9.64M Buy
1,283,289
+696,312
+119% +$4.56M 0.37% 50
2023
Q1 		$2.65M Sell
586,977
-20,493
-3% -$155K 0.12% 64
2022
Q4 		$6.85M Sell
607,470
-144,627
-19% -$1.62M 0.28% 50
2022
Q3 		$7.2M Sell
752,097
-14,700
-2% -$171K 0.28% 55
2022
Q2 		$6.2M Sell
766,797
-5,600
-0.7% -$61K 0.24% 57
2022
Q1 		$13.1M Sell
772,397
-9,700
-1% -$166K 0.41% 50
2021
Q4 		$16.8M Sell
782,097
-82,338
-10% -$3.55M 0.38% 49
2021
Q3 		$63.8M Sell
864,435
-49,600
-5% -$3.31M 1.11% 29
2021
Q2 		$50M Sell
914,035
-64,565
-7% -$3.86M 0.74% 41
2021
Q1 		$72.2M Buy
978,600
+18,200
+2% +$1.43M 1.02% 36
2020
Q4 		$82.8M Buy
960,400
+553,000
+136% +$33.3M 1% 33
2020
Q3 		$15.4M Buy
+407,400
New +$16M 0.28% 59

Other funds holding ALXO

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Redmile Group's ALXO Position: Q2 2026 in Review

Redmile Group reduced its ALX Oncology (ALXO) stake by 7.2% in Q2 2026, selling an estimated $1.02M and leaving 7,392,504 shares worth $15.3M. The position accounts for 1.03% of the portfolio, ranked #21.

Redmile Group first reported a position in ALXO in Q3 2020 and has held it in 24 quarters since. The position peaked at $82.8M in Q4 2020. 94 funds tracked by Wall St. Rank hold ALXO as of Q2 2026.

  • Redmile Group held 7,392,504 shares of ALX Oncology worth $15.3M as of Q2 2026.
  • Redmile Group sold 571,684 ALX Oncology shares in Q2 2026, an estimated $1.02M.
  • ALX Oncology made up 1.03% of Redmile Group's portfolio in Q2 2026, its #21 holding.
  • Redmile Group first reported a position in ALX Oncology in Q3 2020 and has held it in 24 quarters since.
  • Redmile Group's ALX Oncology position peaked at $82.8M in Q4 2020.
  • 94 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2026.

Based on Redmile Group's 13F filing for Q2 2026, filed 14 Aug 2026.